Theranostics — and Beyond

Meets a Passion
for Patient Care

Molecular Targeting Technologies, Inc. is a privately-held clinical stage biotech company developing targeted radiotherapeutics and diagnostics for rare cancers. MTTI has received an exclusive worldwide license from the National Institutes of Health to commercialize targeted theranostics based on EvaThera, an Evans blue (EB)-based technology platform.

For ours Investors

Learn more about EvaThera and Molecular Targeting Technologies. Download our investor deck and partner with us!

Meet The Team

Koon Yan “Chris” Pak, Ph.D.

Chief Executive Officer and Chairman of the Board

Dr. Chris Pak brings three decades of experience in the biopharmaceutical industry. Chris was formerly with Centocor, now a subsidiary of Johnson and Johnson, where he invented and developed novel radiopharmaceuticals and participated in the filing of twelve IND applications for cancer and cardiovascular diseases. He has founded and led multiple societies promoting Nuclear Medicine and Molecular Imaging and entrepreneurship organizations.
Dr. Pak has published more than eighty articles and holds numerous patents on therapeutics and diagnostics. His awards include the 2019 Ernst & Young Entrepreneur of the Year Finalist of Greater Philadelphia, Asian Chamber of Commerce Outstanding Asian American Business Award, Ben Franklin Emerging Business Award, State University of New York Alumni Honor Roll, and the 2014 Lifetime Achievement Award from the Chinese American Society of Nuclear Medicine and Molecular Imaging.

Ji Li, Ph.D.

Chief Operating Officer, Board Director

An accomplished business creator, Dr. Li has orchestrated investment in and headed multiple life science businesses. In addition to his role as COO at MTTI, Dr. Li is President & CEO and co-founder of UFOVAX, Inc. commercializing Scripps Institute’s one component, self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology generating promising candidates for HIV, HCV, Ebola, RSV, MERS and, most recently, COVID-19.
Following his earlier tenure as VP R&D of Rhodia Asia Pacific he became Managing Director, M&A, Technology Development and Pharmaceutical Division and later Group President & CEO for the Feixiang Group. He continues as a Principal in Comway Capital and serves as Board Director of several Biotech startup companies.

Jeffrey A. Mattis, Ph.D

Senior Vice President of Scientific & Regulatory Affairs, Board Director

Dr. Mattis is a biopharmaceutical executive with more than 30 years’ experience in the technical development of biopharmaceuticals. Dr. Mattis previously served as Vice President of Pharmaceutical Development for Centocor. Dr. Mattis was instrumental in the technical development of several biopharmaceuticals approved for the US and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty; Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis; and Myoscint®, a cardiac imaging agent.

Brian D. Gray, Ph.D.

Senior Vice President of Research

Dr Gray has more than 25 years’ experience in the design and synthesis of novel compounds for biomedical research, diagnostics and drug delivery, with special expertise in fluorescent dyes and lipophilic agents. Following a research career at SmithKline Beckman, Dr. Gray co-founded Zynaxis, Inc., a biotech, as Director of Medicinal Chemistry. Later as V.P. of Chemical Research for PTI Research, Inc., he provided contract and custom chemistry services for life sciences and designed novel research reagents for neuronal tract tracing (NeuroVue® dyes) and cell tracking (CellVue® dyes). Dr. Gray earned a Ph.D. from the University of Dundee, Scotland, and carried out post-doctoral research in complex organic molecule synthesis at Oregon State University. He has been Principal Investigator in multiple grants.

Michael Silvon, Ph.D., MBA

Senior Vice President of Business Development

Dr. Silvon has driven profitable, pragmatic life sciences operations over the breadth of small and large molecule drug development; creating, fixing and growing multiple high science, heavily regulated businesses as a senior executive for Charles River Labs, Bioanalytical Systems and ICI/Zeneca. He orchestrated six acquisitions and integrated and ran businesses for three of these long-term. As VP Global Biopharmaceutical Services for Charles River Labs, he restructured and consolidated five global sites into a global leader in molecular biology, virology and microbiology services. Mike advises Chronic Airways Therapeutics and also serves as a Director for Claro Labs and Spark Insights. Mike is also a member of the American Lung Association Covid-19 Advisory Panel.

Learn more about EvaThera
and MTTI

Reach out to us to learn more about EvaThera, MTTI, and the future of radiopharmaceuticals

© 2021 Molecular Targeting Technologies, INC. All Rights Reserved.